Published in Antimicrob Agents Chemother on November 01, 1983
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother (1985) 6.44
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother (1984) 4.13
Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother (1985) 4.07
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother (1984) 4.03
Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother (1984) 3.35
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. Antimicrob Agents Chemother (1984) 3.04
Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother (1984) 2.83
Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother (1984) 2.79
Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare. Antimicrob Agents Chemother (1986) 2.62
A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic. Genome Res (2013) 2.59
Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother (1985) 2.55
Activities of new quinoline derivatives against genital pathogens. Antimicrob Agents Chemother (1985) 2.51
Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother (1985) 2.25
In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob Agents Chemother (1986) 2.02
Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. Antimicrob Agents Chemother (1987) 1.96
Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother (1988) 1.85
In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae. Antimicrob Agents Chemother (1984) 1.80
Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother (1987) 1.78
Tissue penetration of ciprofloxacin after single and multiple doses. Antimicrob Agents Chemother (1986) 1.64
Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother (1992) 1.62
Open, prospective study of the clinical efficacy of ciprofloxacin. Antimicrob Agents Chemother (1985) 1.55
Antimicrobial susceptibilities of Bordetella species isolated in a Multicenter Pertussis Surveillance Project. Antimicrob Agents Chemother (1988) 1.51
Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother (1991) 1.50
Difloxacin metabolism and pharmacokinetics in humans after single oral doses. Antimicrob Agents Chemother (1986) 1.48
Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. Antimicrob Agents Chemother (1986) 1.46
[Dependence of the bactericidal activity and mutant selection of 4-quinolones on their serum concentration levels]. Infection (1986) 1.43
Pharmacokinetics of temafloxacin in humans after single oral doses. Antimicrob Agents Chemother (1991) 1.43
Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks. J Clin Microbiol (1985) 1.38
In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother (1984) 1.31
Pharmacokinetics of three oral formulations of ciprofloxacin. Antimicrob Agents Chemother (1985) 1.31
Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother (1984) 1.26
Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function. Antimicrob Agents Chemother (1987) 1.25
Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin. Antimicrob Agents Chemother (1984) 1.23
In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi. Antimicrob Agents Chemother (1986) 1.20
Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother (1990) 1.18
Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother (1993) 1.17
Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1988) 1.11
Efficacies of various antimicrobial agents in treatment of Staphylococcus aureus abscesses and correlation with in vitro tests of antimicrobial activity and neutrophil killing. Antimicrob Agents Chemother (1991) 1.08
Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs. Antimicrob Agents Chemother (1985) 1.05
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob Agents Chemother (1986) 1.04
Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother (1985) 1.04
Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans. Antimicrob Agents Chemother (1985) 1.03
Ciprofloxacin activity in cyst fluid from polycystic kidneys. Antimicrob Agents Chemother (1988) 1.03
Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. Infection (1988) 1.02
Ciprofloxacin penetration into extravascular spaces in a rabbit model. Antimicrob Agents Chemother (1984) 1.00
Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother (1986) 1.00
Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrob Agents Chemother (1985) 0.99
Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother (1986) 0.97
Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice. Infection (1986) 0.95
Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. Antimicrob Agents Chemother (1991) 0.93
Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection. Antimicrob Agents Chemother (1987) 0.93
Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother (1991) 0.93
Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother (1987) 0.91
Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother (2004) 0.90
Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1991) 0.87
Comparative in vitro antibacterial activity of ofloxacin and ciprofloxacin against some selected gram-positive and gram-negative isolates. Infection (1986) 0.86
Oral ciprofloxacin treatment for Salmonella typhimurium infection of normal and immunocompromised mice. Antimicrob Agents Chemother (1988) 0.83
Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study. Antimicrob Agents Chemother (1992) 0.83
Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother (1990) 0.82
Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases. Infection (1988) 0.82
[Enoxacin concentration in seminal fluid, in prostate secretions and in prostatic adenoma tissue following oral administration or intravenous infusion]. Infection (1989) 0.78
Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br J Pharmacol (2009) 0.78
In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. Infection (1986) 0.78
Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. Antimicrob Agents Chemother (1995) 0.76
Oral ciprofloxacin in the treatment of cholera. Drugs (1995) 0.76
Application of a Physiologically Based Pharmacokinetic Model to Study Theophylline Metabolism and Its Interactions With Ciprofloxacin and Caffeine. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
In vitro activity of 14 antimicrobial agents against Neisseria gonorrhoeae from Spain. Genitourin Med (1987) 0.75
Effects of erythromycin and ciprofloxacin on chronic fecal excretion of Campylobacter species in marmosets. Antimicrob Agents Chemother (1986) 0.75
The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. Infection (1986) 0.75
Ciprofloxacin concentrations in tonsils following single or multiple administrations. Infection (1988) 0.75
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis (1980) 8.40
In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol (1983) 8.38
Drug therapy. Clinical Pharmacokinetics (first of two parts). N Engl J Med (1975) 7.60
Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography. Antimicrob Agents Chemother (1982) 3.24
Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients. J Antimicrob Chemother (1983) 2.42
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis (1980) 8.40
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut (1999) 7.14
General practice fundholding. BMJ (1990) 6.43
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology (2000) 5.40
Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest (1980) 5.11
Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med (1982) 5.07
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother (1978) 4.74
The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology (1996) 4.69
LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 4.52
Antimicrobial resistance. Is a major threat to public health. BMJ (1998) 4.18
Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) (1986) 4.16
The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother (1984) 4.15
Functional anatomy of a common semantic system for words and pictures. Nature (1996) 4.14
Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother (1980) 4.07
Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut (2004) 3.85
Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother (1978) 3.68
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 3.58
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology (2000) 3.58
Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology (1988) 3.51
A new technique for continuous sphincter pressure measurement. Gastroenterology (1976) 3.44
The anatomy of phonological and semantic processing in normal subjects. Brain (1992) 3.41
Rapid diagnosis of Campylobacter-associated gastritis. Lancet (1985) 3.38
In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 3.22
The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol (1998) 3.04
Association of Helicobacter pylori infection with coronary heart disease. Study shows association between H pylori infection and hypertension. BMJ (1996) 3.00
Transient lower esophageal sphincter relaxation. Gastroenterology (1995) 2.91
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet (2001) 2.88
Mupirocin resistance. Lancet (1991) 2.88
Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother (1985) 2.85
Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother (1984) 2.83
Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother (1984) 2.79
Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci (2001) 2.68
Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 2.64
Local surveillance of antimicrobial resistance. Synercid Resistance Surveillance Group. Lancet (1998) 2.60
In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Antimicrob Agents Chemother (1978) 2.58
Pathogenesis of reflux esophagitis. Gastroenterology (1981) 2.58
Reward circuitry activation by noxious thermal stimuli. Neuron (2001) 2.56
Mechanisms of gastroesophageal reflux in ambulant healthy human subjects. Gastroenterology (1995) 2.53
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother (1980) 2.51
The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother (1995) 2.49
Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother (1981) 2.48
In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites. Antimicrob Agents Chemother (1986) 2.45
Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol (1998) 2.44
Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. J Antimicrob Chemother (1998) 2.42
MRI in schistosomiasis of conus medullaris and lumbar spinal cord. Lancet (1993) 2.40
Mycobacterium chelonei isolation from broncho-alveolar lavage fluid and its practical implications. J Hosp Infect (1990) 2.37
A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother (1997) 2.37
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother (1980) 2.35
Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J (1990) 2.33
Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol (2001) 2.23
Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum (1999) 2.22
Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J (2009) 2.18
The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother (1984) 2.15
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother (1982) 2.12
Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther (2009) 2.11
Early and late weight gain following smoking cessation in the Lung Health Study. Am J Epidemiol (1998) 2.10
In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother (1990) 2.09
Behavior and gastroesophageal reflux in the premature neonate. J Pediatr Gastroenterol Nutr (2000) 2.07
Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs. Antimicrob Agents Chemother (1978) 2.07
Hydatidiform mole in England and Wales 1973-83. Lancet (1986) 2.05
In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother (1986) 2.04
In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother (1984) 2.01
Prophylactic use of cephazolin against wound sepsis after cholecystectomy. Br Med J (1977) 1.97
Reproducibility of random amplified polymorphic DNA (RAPD) analysis among laboratories. PCR Methods Appl (1993) 1.97
Clinical and laboratory investigations on ticarcillin, an anti-pseudomonal antibiotic. Chemotherapy (1974) 1.97
Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. Antimicrob Agents Chemother (1987) 1.96
Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1990) 1.95
Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis. Eur J Clin Microbiol (1987) 1.93
Rapid diagnosis of Campylobacter pyloridis gastritis. Lancet (1986) 1.92
The cortical localization of the lexicons. Positron emission tomography evidence. Brain (1992) 1.91
Antropyloroduodenal motor responses to intraduodenal lipid infusion in healthy volunteers. Am J Physiol (1988) 1.89
Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrob Agents Chemother (1980) 1.87
The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother (1986) 1.86
Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology (2000) 1.86
Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. J Antimicrob Chemother (1991) 1.85
Use of antibiotics. Penicillins. Br Med J (1978) 1.85
Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother (1988) 1.85
The pharmacokinetics of LY127935, a broad spectrum oxa-beta-lactam. J Antimicrob Chemother (1980) 1.85
Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother (1992) 1.84
Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother (2001) 1.84
Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother (1992) 1.80
Ceftazidime--a new extended-spectrum cephalosporin. Lancet (1982) 1.79
The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. J Antimicrob Chemother (1989) 1.75
Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels. Antimicrob Agents Chemother (1980) 1.75
Manometric disorders in patients with suspected sphincter of Oddi dysfunction. Gastroenterology (1985) 1.75
Bacteroides fragilis and HR 756. J Antimicrob Chemother (1979) 1.73
Origin of spiral organisms in human gastric antrum. Lancet (1988) 1.72
Upper esophageal sphincter function during deglutition. Gastroenterology (1988) 1.71
Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut (1996) 1.71
Temocillin, in-vitro activity and the pharmacokinetics and tissue penetration in healthy volunteers. J Antimicrob Chemother (1982) 1.70
Mechanisms responsible for gastroesophageal reflux in children. Gastroenterology (1997) 1.70
Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study. J Antimicrob Chemother (1980) 1.68
The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother (1994) 1.68